![](https://www.worldpharmatoday.com/images/nBanners/Docuvera-728x90.jpeg")
Andelyn Biosciences, Inc., a pioneering and patient-focused cell and gene therapy Contract Development and Manufacturing Organization (CDMO), is collaborating with The Ohio State University Gene Therapy Institute for the development and clinical manufacturing of novel gene therapies.
The collaboration was established to facilitate the pathway to bring Ohio State’s investigational gene therapies for a multitude of neurological disorders, such as Parkinson’s, amyotrophic lateral sclerosis (ALS), and Huntington’s, from concept through to manufacturing for clinical trials. Principal investigators at Ohio State will be able to leverage Andelyn’s adherent and suspension platforms and extensive viral vector development and process optimization experience, along with its full manufacturing capabilities. Working together, Ohio State and Andelyn will serve to maximize program efficiencies and accelerate timelines to the clinic.
Developing novel gene therapies together further strengthens the existing working relationship between Ohio State and Andelyn and offers great hope for patients afflicted with genetically based neurological diseases. The strong collaboration between both organizations will ensure Ohio State’s gene therapies are propelled to patients as fast as possible and with the highest quality.
Matt Niloff, Chief Commercial Officer of Andelyn, said: “We are privileged to serve as a critical resource for Ohio State’s premier Gene Therapy Institute, supporting life-changing gene therapy programs with our pre-clinical and GMP manufacturing capabilities.”
Dr. Russell Lonser, Director of Ohio State’s Gene Therapy Institute, commented: “There’s such a critical need to develop effective therapies for ALS, Huntington’s disease and Parkinson’s disease. We believe that gene therapy offers new hope to those suffering from these devastating neurological disorders and look forward to accelerating the development of new transformative therapies.”
With Andelyn’s GMP manufacturing capabilities now established at the state of the art 180,000 sq. ft. Andelyn Corporate Center (ACC), Andelyn is proud to offer its clients exceptional quality and large-scale suspension clinical and commercial manufacturing in the Columbus, Ohio biotech hub. The ACC augments Andelyn’s two other Columbus facilities offering pre-clinical process development and plasmid manufacturing.
